EGFR and non-small cell lung carcinoma: Two patients with these mutations in our study had a slightly longer DFS (13.3 and 16.4 months) than in single mutation either del19 or L858R EGFR mutant NSCLC, which reported in the previous phase 3 studies (9.5–13.6 months) [5, 7, 12, 41].